{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T14:12:50Z","timestamp":1717942370020},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":501,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq)"},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ)"},{"name":"Institutos Nacionais de Ci\u00eancia e Tecnologia"},{"name":"INCT para Controle do C\u00e2ncer"},{"name":"CNPq 573806\/2008-0"},{"name":"FAPERJ","award":["EE26\/170.026\/2008"],"award-info":[{"award-number":["EE26\/170.026\/2008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.leukres.2012.08.014","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T21:01:33Z","timestamp":1347310893000},"page":"1510-1516","source":"Crossref","is-referenced-by-count":7,"title":["Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells"],"prefix":"10.1016","volume":"36","author":[{"given":"Paula Sabbo","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaviana Ruade de Souza","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.08.014_bib0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2004.03.005","article-title":"Accelerated and blastic phases of chronic myelogenous leukemia","volume":"18","author":"Giles","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2012.08.014_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11864-006-0012-y","article-title":"Blastic phase of chronic myelogenous leukemia","volume":"7","author":"Karbasian Esfahani","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2012.08.014_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.014_bib0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.leukres.2012.08.014_bib0030","series-title":"The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","author":"Moraes","year":"2012"},{"key":"10.1016\/j.leukres.2012.08.014_bib0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.leukres.2012.08.014_bib0040","doi-asserted-by":"crossref","first-page":"33450","DOI":"10.1074\/jbc.C600164200","article-title":"Separating the anti-apoptotic and mitotic roles of survivin","volume":"281","author":"Colnaghi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2012.08.014_bib0045","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/CAD.0b013e3283140c6f","article-title":"Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation","volume":"19","author":"Kwee","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.leukres.2012.08.014_bib0050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1242\/jcs.115.3.575","article-title":"Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function","volume":"115","author":"Fortugno","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.leukres.2012.08.014_bib0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ijc.20768","article-title":"Nuclear or cytoplasmic expression of survivin: what is the significance?","volume":"114","author":"Li","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2012.08.014_bib0060","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1248\/bpb.30.2279","article-title":"The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells","volume":"30","author":"Liu","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.leukres.2012.08.014_bib0065","first-page":"1469","article-title":"Survivin transcription is associated with P-glycoprotein\/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells","volume":"23","author":"Liu","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1016\/j.leukres.2012.08.014_bib0070","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.leukres.2012.08.014_bib0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","article-title":"Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"An Acad Bras Cienc"},{"key":"10.1016\/j.leukres.2012.08.014_bib0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-5956-10-23","article-title":"A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line","volume":"10","author":"Correa","year":"2012","journal-title":"Proteome Sci"},{"key":"10.1016\/j.leukres.2012.08.014_bib0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2012.08.014_bib0090","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Maia","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.leukres.2012.08.014_bib0095","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10495-006-3560-5","article-title":"Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia","volume":"11","author":"Silva","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2012.08.014_bib0105","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1158\/0008-5472.CAN-08-0817","article-title":"Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis","volume":"68","author":"Connell","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.08.014_bib0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2012.08.014_bib0115","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp070482","article-title":"Targeted chronic myeloid leukemia therapy: seeking a cure","volume":"64","author":"Fausel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.leukres.2012.08.014_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1432-1327.1998.2510155.x","article-title":"Multidrug-resistance drug-binding peptides generated by using a phage display library","volume":"251","author":"Popkov","year":"1998","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.leukres.2012.08.014_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2141.2001.02979.x","article-title":"Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy","volume":"114","author":"Mansson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0130","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2012.08.014_bib0135","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.014_bib0140","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.014_bib0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2402041","article-title":"Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells","volume":"15","author":"Topaly","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.014_bib0150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4161\/cc.6.5.3902","article-title":"Survivin's dual role: an export's view","volume":"6","author":"Knauer","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2012.08.014_bib0155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/sj.bjc.6600776","article-title":"Prognostic importance of survivin in breast cancer","volume":"88","author":"Kennedy","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2012.08.014_bib0160","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdh436","article-title":"Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer","volume":"15","author":"Vischioni","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0165","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/sj.bjc.6602632","article-title":"Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients","volume":"92","author":"Tonini","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2012.08.014_bib0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.bjc.6602904","article-title":"Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma","volume":"94","author":"Xie","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2012.08.014_bib0175","first-page":"557","article-title":"Intracellular localization of survivin determines biological behavior in colorectal cancer","volume":"22","author":"Qi","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.leukres.2012.08.014_bib0180","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/sj.cdd.4401091","article-title":"Differential subcellular localization of functionally divergent survivin splice variants","volume":"9","author":"Mahotka","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.leukres.2012.08.014_bib0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2011.01.010","article-title":"Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses","volume":"139","author":"Speletas","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/01.jnen.0000235857.79502.c3","article-title":"Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules","volume":"65","author":"Liu","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12253-011-9401-z","article-title":"Lack of prognostic significance of survivin in pediatric medulloblastoma","volume":"17","author":"Faccion","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.leukres.2012.08.014_bib0200","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/jclinpath-2011-200066","article-title":"Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma","volume":"64","author":"Huang","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.leukres.2012.08.014_bib0205","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1373\/clinchem.2006.071613","article-title":"Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?","volume":"52","author":"Span","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.leukres.2012.08.014_bib0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2012.08.014_bib0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.leukres.2009.11.004","article-title":"Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines","volume":"34","author":"Marques","year":"2010","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T17:02:41Z","timestamp":1643389361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612003475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0145212612003475"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.08.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}